Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Sanger Sequencing01:57

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aardvark: sifting through differences in a mound of variants.

Genome biology·2026
Same author

TriosCompass: a snakemake workflow for integrated detection of SNVs, indels, STRs, and structural de novo variants in parent-child trios.

Bioinformatics (Oxford, England)·2026
Same author

Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.

Nature communications·2026
Same author

A Murine Database of Structural Variants Identifies A Candidate Gene for a Spontaneous Murine Lymphoma Model.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

LCSkPOA: enabling banded semi-global partial order alignments via efficient and accurate backbone generation through extended LCSk+.

BMC bioinformatics·2025
Same author

Risk of clonal hematopoiesis in families exposed to radiation following the Chornobyl accident.

Carcinogenesis·2025

Related Experiment Video

Updated: May 22, 2026

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.

Christopher T Saunders1, Wendy S W Wong, Sajani Swamy

  • 1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA. csaunders@illumina.com

Bioinformatics (Oxford, England)
|May 15, 2012
PubMed
Summary

Strelka is a new Bayesian method for detecting somatic single nucleotide variants (SNVs) and small indels in cancer sequencing data. It accurately identifies variants even in samples with high tumor impurity, outperforming existing methods.

More Related Videos

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Area of Science:

  • Genomics
  • Cancer Research
  • Bioinformatics

Background:

  • Whole genome and exome sequencing of matched tumor-normal samples is standard in cancer research.
  • Increased demand for somatic variant analysis necessitates specialized methods for handling tumor impurity.

Purpose of the Study:

  • To introduce Strelka, a novel method for somatic single nucleotide variant (SNV) and small indel detection.
  • To address the challenge of accurately calling variants in cancer samples with varying levels of tumor purity.

Main Methods:

  • Strelka employs a Bayesian approach to model continuous allele frequencies in tumor and normal samples.
  • It leverages the expected genotype of the normal sample and models the tumor as a mixture of normal and somatic variations.
  • The method does not require explicit tumor purity estimates.

Main Results:

  • Strelka demonstrates superior accuracy and sensitivity in detecting somatic SNVs and small indels, particularly in impure samples.
  • The method maintains high sensitivity even at high tumor impurity levels.
  • Performance surpasses existing approaches based on diploid genotype likelihoods or general allele-frequency tests.

Conclusions:

  • Strelka provides a robust and sensitive solution for somatic variant detection in cancer research.
  • Its ability to handle tumor impurity without purity estimates makes it a valuable tool for routine analysis.
  • The method enhances the accuracy and sensitivity of variant calling in diverse cancer sequencing datasets.